Mode
Text Size
Log in / Sign up
N/A N=399 Randomized Single-blind Supportive Care

Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa

HIV/AIDS · Violence

Enrolled (actual)
399
Serious AEs
3.3%
Results posted
Feb 2026
Primary outcome: Primary: 12 Month Viral Suppression — 86; 86 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CETA (Behavioral); Short Message Service (SMS) text reminders (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Boston University
Primary completion
May 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
12 Month Viral Suppression
86; 86
SECONDARY
3 Month Viral Suppression
25; 13
SECONDARY
12 Month Attrition Rate
49; 38
SECONDARY
Violence Against Women at 3 Months
37.0; 37.0
SECONDARY
Violence Against Women at 12 Months
35.2; 37.1
SECONDARY
Substance Use at 3 Months
0.1; 0.1
SECONDARY
Substance Use at 12 Months
0.1; 0.2
SECONDARY
Post-traumatic Stress Disorder (PTSD) Symptoms at 3 Months
1.6; 1.8
SECONDARY
Post-traumatic Stress Disorder (PTSD) Symptoms at 12 Months
1.7; 1.9
SECONDARY
Depression Based on the Epidemiological Studies-Depression Scale (CES-D) Scale Score at 3 Months
15.3; 16.1
SECONDARY
Depression Based on the Epidemiological Studies-Depression Scale (CES-D) Scale Score at 12 Months
16.7; 20.1

Summary

This study will evaluate the impact of the Common Elements Treatment Approach (CETA), an evidence-based intervention comprised of cognitive-behavioral therapy elements, at improving HIV treatment outcomes among women with HIV who have experienced intimate partner violence (IPV) and have an unsuppressed viral load on HIV treatment. To evaluate CETA, the investigators will conduct a randomized controlled trial of HIV-infected women, with or without their partners, who have experienced IPV and have an unsuppressed viral load to test the effect of CETA in increasing viral suppression and reducing violence. The investigators will also identify mediators and moderators of CETA's effect on retention and viral suppression and assess the cost and cost-effectiveness of CETA vs. active control at increasing the proportion who are retained and virally suppressed by 12 months.

Eligibility Criteria

Inclusion Criteria

  • Adult HIV positive women
  • Initiated HIV treatment
  • Most recent viral load >50 copies/mL or they have defaulted from treatment or had a missed or late (>14 days) visit in the last year
  • Has experienced IPV in the past 12 months
  • Has their own phone and can receive text messages
  • Literate and able to speak and read one of: English, Zulu, SeSotho
  • If including a partner, the woman has disclosed HIV status to the partner that will be invited to participate (noting that male partners are not study subjects, only the woman is)

Exclusion Criteria

  • Unwilling to complete the informed consent process
  • Currently psychotic or on unstable psychiatric regimen
  • Suicide attempt/ideation with intent and plan, and/or self-harm in the past month
  • Enrolled in any other HIV treatment intervention study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04242992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search